Zhongtai Securities Maintains "Buy" on 3SBIO, Citing Unlocked Market Value Potential

Deep News05-17

Zhongtai Securities Co.,Ltd. has issued a research report, projecting that 3SBIO (01530) will achieve operating revenues of RMB 9.706 billion, RMB 11.326 billion, and RMB 12.870 billion for the years 2026, 2027, and 2028, respectively. Previous forecasts for 2026-2027 revenues were RMB 11.494 billion and RMB 13.153 billion. The company is also expected to report net profits attributable to shareholders of RMB 2.268 billion, RMB 3.158 billion, and RMB 3.666 billion for the same periods, compared to prior estimates of RMB 2.648 billion and RMB 3.027 billion for 2026-2027. The minor adjustments are primarily based on extrapolations from the domestic drug commercialization situation in 2025. The overseas partnership for project 707 remains stable, and the ceiling for the company's market value is now considered to have been lifted. The "Buy" rating is maintained.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139585846?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-17 11:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139585846","market":"nz","top_or_hot":-1,"title":"Zhongtai Securities Maintains \"Buy\" on 3SBIO, Citing Unlocked Market Value Potential","media":"Deep News","content":"<p>Zhongtai Securities Co.,Ltd. has issued a research report, projecting that 3SBIO (01530) will achieve operating revenues of RMB 9.706 billion, RMB 11.326 billion, and RMB 12.870 billion for the years 2026, 2027, and 2028, respectively. Previous forecasts for 2026-2027 revenues were RMB 11.494 billion and RMB 13.153 billion. The company is also expected to report net profits attributable to shareholders of RMB 2.268 billion, RMB 3.158 billion, and RMB 3.666 billion for the same periods, compared to prior estimates of RMB 2.648 billion and RMB 3.027 billion for 2026-2027. The minor adjustments are primarily based on extrapolations from the domestic drug commercialization situation in 2025. The overseas partnership for project 707 remains stable, and the ceiling for the company's market value is now considered to have been lifted. The \"Buy\" rating is maintained.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhongtai Securities Maintains \"Buy\" on 3SBIO, Citing Unlocked Market Value Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhongtai Securities Maintains \"Buy\" on 3SBIO, Citing Unlocked Market Value Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-05-17 11:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhongtai Securities Co.,Ltd. has issued a research report, projecting that 3SBIO (01530) will achieve operating revenues of RMB 9.706 billion, RMB 11.326 billion, and RMB 12.870 billion for the years 2026, 2027, and 2028, respectively. Previous forecasts for 2026-2027 revenues were RMB 11.494 billion and RMB 13.153 billion. The company is also expected to report net profits attributable to shareholders of RMB 2.268 billion, RMB 3.158 billion, and RMB 3.666 billion for the same periods, compared to prior estimates of RMB 2.648 billion and RMB 3.027 billion for 2026-2027. The minor adjustments are primarily based on extrapolations from the domestic drug commercialization situation in 2025. The overseas partnership for project 707 remains stable, and the ceiling for the company's market value is now considered to have been lifted. The \"Buy\" rating is maintained.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1139585846","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139585846","pubTimestamp":1778988043,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Zhongtai Securities Co.,Ltd. has issued a research report, projecting that 3SBIO (01530) will achieve operating revenues of RMB 9.706 billion, RMB 11.326 billion, and RMB 12.870 billion for the years...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600918":"中泰证券","01530":"三生制药","BK1593":"医美概念股","BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1583":"高瓴概念","BK0276":"资本市场"},"translate_title":"中泰证券维持三生制药“买入”，称市值潜力未被锁定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600918":1,"01530":1},"content_text":"Zhongtai Securities Co.,Ltd. has issued a research report, projecting that 3SBIO (01530) will achieve operating revenues of RMB 9.706 billion, RMB 11.326 billion, and RMB 12.870 billion for the years 2026, 2027, and 2028, respectively. Previous forecasts for 2026-2027 revenues were RMB 11.494 billion and RMB 13.153 billion. The company is also expected to report net profits attributable to shareholders of RMB 2.268 billion, RMB 3.158 billion, and RMB 3.666 billion for the same periods, compared to prior estimates of RMB 2.648 billion and RMB 3.027 billion for 2026-2027. The minor adjustments are primarily based on extrapolations from the domestic drug commercialization situation in 2025. The overseas partnership for project 707 remains stable, and the ceiling for the company's market value is now considered to have been lifted. The \"Buy\" rating is maintained.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139585846","isCrawlerRequest":true}